Spots Global Cancer Trial Database for DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis

Official Title: Advanced CT Imaging Optimization for the Detection of Intracranial Metastasis

Study ID: NCT03685539

Conditions

Malignant Neoplasm

Metastatic Malignant Neoplasm in the Brain

Interventions

Dual-Energy Computed Tomography

Study Description

Brief Summary: This trial studies how well dual energy computed tomography (DECT) works in imaging patients with solid organ cancer that has spread to the brain. Imaging techniques, such as DECT, may help find and diagnose tumor cells and find out how far the tumor cells have spread in the brain.

Detailed Description: PRIMARY OBJECTIVES: I. To optimize two major parameters of computed tomography (CT) imaging for optimal detection of intracranial metastatic lesions. Ia. Virtual monochromatic image reconstruction. Ib. Contrast bolus timing. II. To measure the detection accuracy of CT compared to the diagnostic standard of care gadolinium-based "Gamma Knife (GK)" protocol magnetic resonance imaging (MRI). OUTLINE: Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.